Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:22pm EDT

Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX®(eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products

Media Contact:

Kim.bencker@pfizer.com

610-329-1340

For Immediate Release- NEW YORK, NY, August 14, 2019.

Pfizer Inc. is voluntarily recalling RELPAX®(eletriptan hydrobromide) 40 mg tablets, lots AR5407 and CD4565, to the Patient level. Pfizer Inc. initiated this recall because these product lots may not meet Pfizer's in-house microbiological specification for the potential presence of Genus Pseudomonas and Burkholderia.

Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections. In addition, there is risk of temporary gastrointestinal distress without serious infection. For the general population these risks are low; for certain vulnerable patient populations (such as patients with compromised immune systems, cystic fibrosis and chronic granulomatous disease) there may be the potential for serious adverse events including life- threatening infections. To date, Pfizer has not received any customer complaints or reports of adverse events related to this issue.

RELPAX®(eletriptan hydrobromide) is indicated for the acute treatment of migraine with or without aura in adults.

RELPAX ® (eletriptan hydrobromide) 40 mg tablets are packaged in cartons as indicated below. The affected lots were distributed nationwide to wholesalers, retailers, hospitals, and healthcare providers in the United States and Puerto Rico from June 2019, to July 2019.

Carton NDC

Lot

Expiration

Strength

Configuration/Count

Number

Date

0049-2340-45

AR5407

2022

FEB

40

mg

Carton containing 6 tablets

(1 blister card x 6 tablets)

0049-2340-05

CD4565

2022

FEB

40

mg

Carton containing 12

tablets

(2 blister cards x 6

tablets)

Pfizer Inc. places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer Inc. has notified its direct customers via a recall letter to arrange for return of any recalled product.

Anyone with an existing inventory of the lots, which are being recalled, should stop use and distribution and quarantine immediately. Inform healthcare professionals in your organization of this recall. For retailers, hospitals, or healthcare providers that have dispensed product to patients, please notify these patients regarding the recall. For additional assistance, call Stericycle at 877-225-9750 (Monday through Friday, 8 a.m. to 5 p.m. ET).

For clinical inquiries, please contact Pfizer using the below information.

Contact Center

Contact Information

Area of Support

Pfizer Medical

800-438-1985, option 3

For medical questions

(Monday through Friday 9am to 5pm

regarding this

Information

ET)

product

800-438-1985, option 1 (24 hours a

To report adverse

Pfizer Drug Safety

day 7 days per week)

events or product

complaints

Patients who are taking this product should consult with their

healthcare provider or pharmacy to determine if they have the

affected product lots. Patients with the affected lots should return the product to their pharmacy or contact Stericycle Inc. at 877-225-9750 for instructions on how to return their product and obtain reimbursement for their cost.

If you have received free product through the Pfizer Patient Assistance Program (PAP) or the Pfizer Institutional Patient Assistance Program (IPAP), please check if you have received any of the affected product lots above. If you have any of the affected product lots in your possession, please contact your healthcare provider to return the product to them.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the reportOnline:www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download formwww.fda.gov/MedWatch/getforms.htmor call1-800-332-1088to request a reporting form, then complete and return to the address on thepre-addressedform, or submit by fax
    to 1-800-FDA-0178.

This recall is being executed with the knowledge of the U.S. Food and Drug Administration.

# # # # #

Carton Front View for 40 mg RELPAX® (eletriptan hydrobromide)

tablets

Disclaimer

Pfizer Inc. published this content on 14 August 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2019 21:21:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
07:33aElanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
07:27aElanco to become No.2 in animal health with $7.6 billion Bayer deal
RE
07:01aTHE PFIZER FOUNDATION : Invests in 20 Organizations Tackling Infectious Diseases..
BU
08/19Who is next in big pharma's merger spree?
RE
08/16FITCH RTGS : US Pharma M&A, Portfolio Reshaping, R&D Offset Growth Risk
AQ
08/15Pfizer Recalls Two Lots of Relpax Over Possible Contamination
DJ
08/14PFIZER : Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® (eletriptan ..
PU
08/14PFIZER : Oncolytics Biotech Reports 2019 Second Quarter Financial Results and Op..
AQ
08/14Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt
RE
08/13PFIZER : City moves who's switching jobs
AQ
More news
Financials (USD)
Sales 2019 51 749 M
EBIT 2019 18 934 M
Net income 2019 11 493 M
Debt 2019 30 778 M
Yield 2019 4,08%
P/E ratio 2019 15,2x
P/E ratio 2020 14,9x
EV / Sales2019 4,35x
EV / Sales2020 4,59x
Capitalization 195 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,77  $
Last Close Price 35,18  $
Spread / Highest target 56,3%
Spread / Average Target 24,4%
Spread / Lowest Target -6,20%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-20.62%194 582
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
ROCHE HOLDING13.20%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341